Hundreds of firms join global hunt for copycat biotech drugs
September 29, 2014 at 05:59 AM EDT
Sept 29 (Reuters) - Hundreds of companies around the world are chasing an emerging market for cheaper copies of costly biotech drugs, with more than 700 so-called biosimilars now in development or already approved, according to a major study of the sector.